Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Ass...(nsinvestors that there can be no assuran...),Health

Date:5/12/2008

ns investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements. Please refer to our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007, and to our subsequent Quarterly Reports on Form 10-Q, for a description of risks that may affect our results or business conditions. The Company does not undertake any obligation to publicly release the result of any revisions to such forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events except as required by law. SEPET(TM) and HepatAssist(TM) are trademarks of Arbios Systems, Inc.

'/>"/>

SOURCE Arbios Systems, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
2. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
3. Strykers Biotech Division Receives FDA Warning Letter
4. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
5. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
6. Genta Receives Key Patent Related to Oral Gallium Compound G4544
7. QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS
8. Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
9. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
10. DermaGen AB Receives Over 1 Million Euros From a New Share Issue
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.